Kairos Pharma (KAPA) Return on Capital Employed (2024 - 2025)

Kairos Pharma's (KAPA) quarterly Return on Capital Employed came in at 68.65% in Q2 2025, down 25.17% on a QoQ basis from 54.85% in Q1 2025.

Kairos Pharma (KAPA) Return on Capital Employed (2024 - 2025) Analysis & Trends

Kairos Pharma (KAPA) has 2 years of Return on Capital Employed data on file, last reported at 68.65% in Q2 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 68.65% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 68.65% (changed N/A YoY) and the FY2025 annual result came in at 93.57%, up 510.0% from the prior year.
Return on Capital Employed retreated to 68.65% in Q2 2025, from 54.85% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 53.21% in Q4 2024 to a low of 68.65% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	10.74%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	26.09%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-6.85%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	7.88%
10	Kairos Pharma	5.39 Mn	55,970.58	-	-

Download Data